CURRICULUM VITAE AND BIBLIOGRAPHY – ANTONIO ROSATO

PERSONAL

Name: Antonio Rosato
Place of bith: Camposampiero (Padova), Italy
Date of birth: June 09, 1964
Citizenship: Italian
Address: Via San Giuliano 1, 35010 Borgoricco (PD) Tel: +39-49-9335551 (home); +39-49-8215858 (office); Fax: +39-49-8072854; e-mail: antonio.rosato@unipd.it

PERMANENT EMPLOYMENT

10/01/2014 - present: Associate Professor of Immunology, Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padova, Italy
17/02/1999 - 09/30/2014: Assistant Professor, Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padova, Italy

EDUCATION

July 1983: High School Diploma (60/60) at “Liceo Classico C. Marchesi", Padova
July-August 1987: Visiting Medical Student at the "Bone Marrow Transplant Unit", University of San Francisco (U.S.A.)
July 1991: Medical Degree (M.D.), summa cum laude, University of Padova
August 1991: Visiting Graduate at the Department of Medical Oncology, University of Uppsala (Sweden)
December 1991: Medical Licensing Examination, University of Padova
March-May 1993: Visiting Scientist at the Kennedy Institute of Rheumatology (Sunley Division), University of London (winner of a "short-term fellowship" from the European Molecular Biology Organisation (E.M.B.O.)
May 1993: Visiting Scientist at the Department of Anatomy, University of Birmingham (U.K.)
August and September 1995: “United States Medical Licensing Examination” (USMLE) Step 1 e Step 2 (certificate n. 0-541-710-0)
November 1995: Specialization (70/70 with honors) in Allergy and Clinical Immunology, University of Padova
February 1999: Ph.D. Degree in Oncology, University of Padova

FELLOWSHIPS AND SCIENTIFIC AWARDS

1991-1995: fellowship from the Italian Ministry of Education for Specialization
1993: short-term fellowship from the European Molecular Biology Organisation, EMBO
1995: "Virgilio Chini" award for Degree thesis
1995: "Lorenza Cescatti" award from Fondazione Trentina per la Ricerca sui Tumori
1995-1998: fellowship from the Italian Ministry of Education for Ph.D.

GRANTS AND FUNDING

Since February 1999, when he got his first permanent position at the University, Prof. Antonio Rosato has been and is currently responsible for different research projects funded by public and private institutions, which collectively account for over 5.0 Meuro.

PUBLICATIONS

1. Porcù E, Maule F, Boso D, Rampazzo E, Barbieri V, Zuccolotto G, **Rosato A**, Frasson C, Viola G, Puppa AD, Basso G, Persano L. BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. Cell Death Differ. 2018 Jul 5. doi: 10.1038/s41418-018-0149-9. [Epub ahead of print].
2. Bellazzo A, Di Minin G, Valentino E, Sicari D, Torre D, Marchionni L, Serpi F, Stadler MB, Taverna D, Zuccolotto G, Montagner IM, **Rosato A**, Tonon F, Zennaro C, Agostinis C, Bulla R, Mano M, Del Sal G, Collavin L. Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. Cell Death Differ, 2018;25:1224-1238.
3. Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, Severino LU, Scaini D, Mano M, Mantovani F, **Rosato A**, Bicciato S, Piccolo S, Del Sal G. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. Nat Cell Biol, 2018;20:28-35.
4. Biscaglia F, Rajendran S, Conflitti P, Benna C, Sommaggio R, Litti L, Mocellin S, Bocchinfuso G, **Rosato A**, Palleschi A, Nitti D, Gobbo M, Meneghetti M. Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide. Adv Healthc Mater, 2017, doi: 10.1002/adhm.201700596. [Epub ahead of print]
5. Tosi A, Dalla Santa S, Cappuzzello E, Marotta C, Walerich D, Del Sal G, Zanovello P, Sommaggio R, **Rosato A**. Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. OncoImmunology, 2017;6:e1313371.
6. Cappuzzello E, Sommaggio R, Zanovello P, **Rosato A**. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine Growth Factor Rev, 2017;36:99-105.
7. Abozeid M, **Rosato A**, Sommaggio R. Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. Biomed Res Int, 2017;2017:5791262.
8. Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, Kalid O, Golan G, Baloglu E, Shacham S, Valsasina B, Cucchi U, Pippione AC, Lolli ML, Giabbai B, Storici P, Carloni P, Rossetti G, Benvenuti F, Bello E, D'Incalci M, Cappuzzello E, **Rosato A**, Del Sal G. A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nat Commun, 2017;8:15772.
9. Turrini R, Merlo A, Martorelli D, Faè DA, Sommaggio R, Montagner IM, Barbieri V, Marin O, Zanovello P, Dolcetti R, **Rosato A**. A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. OncoImmunology, 2017;6:e1304338.
10. Muraro E, Merlo A, Martorelli D, Cangemi M, Dalla Santa S, Dolcetti R, **Rosato A**. Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic $CD4^+$ T Cells. Front Immunol, 2017;8:197.
11. Balasso A, Salmaso S, Pontisso P, **Rosato A**, Quarta S, Malfanti A, Mastrotto F, Caliceti P. Re-programming pullulan for targeting and controlled release of

doxorubicin to the hepatocellular carcinoma cells. Eur J Pharm Sci, 2017;pii:S0928-987(17)30078-7.

12. Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, Neri C, Cappuzzello E, Forcato M, **Rosato A**, Mano M, Bicciato S, Del Sal G. Glucocorticoid receptor signalling activates YAP in breast cancer. Nat Commun, 2017;8:14073.
13. Mandracchia D, **Rosato A**, Trapani A, Chlapanidas T, Montagner IM, Perteghella S, Di Franco C, Torre ML, Trapani G, Tripodo G. Design, synthesis and evaluation of biotin decorated inulin-based polymeric micelles as long-circulating nanocarriers for targeted drug delivery. Nanomedicine, 2017;13:1245-1254.
14. De Luca A, Carpanese D, Rapanotti MC, Viguria TM, Forgione MA, Rotili D, Fulci C, Iorio E, Quintieri L, Chimenti S, Bianchi L, **Rosato A***, Caccuri AM. The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis. Oncotarget, 2017;8:15520-15538.2017 ***Co-corresponding author**.
15. Dalzoppo D, Di Paolo V, Calderan L, Pasut G, **Rosato A**, Caccuri AM, Quintieri L. Thiol-Activated Anticancer Agents: The State Of The Art. Anticancer Agents Med Chem, 2017;17:4-20.
16. Spolaore B, Raboni S, Satwekar AA, Grigoletto A, Mero A, Montagner IM, **Rosato A**, Pasut G, Fontana A. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues. Bioconjug Chem, 2016;27:2695-2706.
17. Frigo G, Tramentozzi E, Orso G, Ceolotto G, Pagetta A, Stagni C, Menin C, **Rosato A***, Finotti P. Human IgGs induce synthesis and secretion of IgGs and neonatal Fc receptor in human umbilical vein endothelial cells. Immunobiology, 2016;221:1329-1342. ***Co-corresponding author**.
18. Carta D, Salvarese N, Morellato N, Gao F, Sihver W, Pietzsch HJ, Biondi B, Ruzza P, Refosco F, Carpanese D, **Rosato A**, Bolzati C. Melanoma targeting with [^{99m}Tc(N)(PNP3)]-labeled α-melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties. Nucl Med Biol, 2016;43:788-801.
19. Panciera T, Azzolin L, Fujimura A, Di Biagio D, Frasson C, Bresolin S, Soligo S, Basso G, Bicciato S, **Rosato A**, Cordenonsi M, Piccolo S. Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. Cell Stem Cell. 2016;19:725-737.
20. Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, **Rosato A**. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016;5:e1199311.
21. Dalle Carbonare L, Vilei MT, Stranieri C, Innamorati G, **Rosato A**, Boldrin E, Sella S, Giannini S, Valenti MT. Fast method for skeletal tissue gene expression analysis. Biomed Rep, 2016;5:248-250.
22. Montagner IM, Merlo A, Carpanese D, Dalla Pietà A, Mero A, Grigoletto A, Loregian A, Renier D, Campisi M, Zanovello P, Pasut G, **Rosato A**. A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer. J Control Release, 2016;236:79-89.

23. Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, **Rosato A**, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Res, 2016;76:4775-84.

24. Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C, Morelli MJ, Amato A, Eterno V, Zambelli A, **Rosato A**, Amati B, Wiśniewski JR, Del Sal G. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol, 2016;18:897-909.

25. Tosatto A, Sommaggio R, Kummerow C, Bentham RB, Blacker TS, Berecz T, Duchen MR, **Rosato A**, Bogeski I, Szabadkai G, Rizzuto R, Mammucari C. The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1α. EMBO Mol Med, 2016;8:569-85.

26. Merlo A, Santa SD, Dolcetti R, Zanovello P, **Rosato A**. Reverse immunoediting: When immunity is edited by antigen. Immunol Lett, 2016;175:16-20.

27. Faè DA, Martorelli D, Mastorci K, Muraro E, Dal Col J, Franchin G, Barzan L, Comaro E, Vaccher E, **Rosato A**, Dolcetti R. Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. Cancer Immunol Res, 2016;4:431-40.

28. Piccoli M, Urbani L, Alvarez-Fallas ME, Franzin C, Dedja A, Bertin E, Zuccolotto G, **Rosato A**, Pavan P, Elvassore N, De Coppi P, Pozzobon M. Improvement of diaphragmatic performance through orthotopic application of decellularized extracellular matrix patch. Biomaterials, 2016;74:245-55.

29. Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, **Rosato A**, Bicciato S, Cordenonsi M, Piccolo S. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol, 2015;17:1218-27.

30. Montagner IM, Merlo A, Carpanese D, Zuccolotto G, Renier D, Campisi M, Pasut G, Zanovello P, **Rosato A**. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience, 2015;2:373-81.

31. Mazzocco M, Martini M, **Rosato A**, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, Bronte V, Sartoris S. Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. Immunology, 2015;146:33-49.

32. Quici S, Casoni A, Foschi F, Armelao L, Bottaro G, Seraglia R, Bolzati C, Salvarese N, Carpanese D, **Rosato A**. Folic acid-conjugated europium complexes as luminescent probes for selective targeting of cancer cells. J Med Chem, 2015;58:2003-14.

33. De Luca A, Rotili D, Carpanese D, Lenoci A, Calderan L, Scimeca M, Mai A, Bonanno E, **Rosato A***, Geroni C, Quintieri L, Caccuri AM. A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and

selective antitumor activity against human melanoma xenografts. Oncotarget, 2015;6:4126-43. ***Co-corresponding author.**

34. Mero A, Campisi M, Caputo M, Cuppari C, **Rosato A**, Schiavon O, Pasut G. Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone. Curr Drug Targets, 2015;16:1503-11.

35. Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, Piazza S, Rami D, Bulla R, Sommaggio R, **Rosato A**, Del Sal G, Collavin L. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell, 2014;56:617-29.

36. Montagner IM, Merlo A, Zuccolotto G, Renier D, Campisi M, Pasut G, Zanovello P, **Rosato A**. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. Plos One, 2014;9:e112240.

37. Salvarese N, Morellato N, **Rosato A**, Meléndez-Alafort L, Refosco F, Bolzati C. Novel [99mTcIII(PS)2(Ln)] mixed-ligand compounds (PS= phosphino-thiolate; L= dithiocarbamate) useful in design and development of TcIII-based agents: synthesis, in vitro and ex vivo biodistribution studies. J Med Chem, 2014;57:8960-8970.

38. Zuccolotto G, Fracasso G, Montagner IM, Merlo A, Rondina M, Bobisse S, Figini M, Cingarlini S, Colombatti M, Zanovello P, **Rosato A**. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. Plos One, 2014;9:e109427.

39. Dalla Santa S, Merlo A, Bobisse S, Ronconi E, Boldrin D, Milan G, Barbieri V, Marin O, Facchinetti A, Biasi G, Dolcetti R, Zanovello P, **Rosato A**. Functional avidity-driven activation-induced cell death shapes CTL Immunodominance. J Immunol, 2014;193:4704-4711.

40. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, **Rosato A**, Piccolo S, Del Sal G. Metabolic control of YAP/TAZ by the mevalonate pathway. Nat Cell Biol, 2014;16:357-366.

41. Amendola V, Scaramuzza S, Litti L, Meneghetti M, Zuccolotto G, **Rosato A**, Nicolato E, Marzola P, Fracasso G, Pinto M, Colombatti M. Magneto-plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging. Small, 2014;10:2476-2486.

42. Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F, Santarpia L, Aifantis I, **Rosato A**, Bicciato S, Zambelli A, Del Sal G. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med, 2014;6:99-119.

43. Bigini P, Previdi S, Casarin E, Silvestri D, Violatto MB, Facchin S, Sitia L, **Rosato A**, Zuccolotto G, Realdon N, Fiordaliso F, Salmona M, Morpurgo M. In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. ACS Nano, 2014;8:175-187.

44. Alaggio R, Turrini R, Boldrin D, Merlo A, Gambini C, Ferrari A, Dall'igna P, Coffin CM, Martines A, Bonaldi L, De Salvo GL, Zanovello P, **Rosato A**. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). Plos One, 2013;8:e80456.

45. Montagner IM, Banzato A, Zuccolotto G, Renier D, Campisi M, Bassi P, Zanovello P, **Rosato A**. Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines. Urol Oncol, 2013;31:1261-1269.

46. **Rosato A**, Menin C, Boldrin D, Santa SD, Bonaldi L, Scaini MC, Del Bianco P, Zardo D, Fassan M, Cappellesso R, Fassina A. Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer, 2013;79:180-186.

47. Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, **Rosato A**, Colombatti M, Canevari S, Figini M. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur J Cancer, 2013;49:2223-2232.

48. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, **Rosato A**, Sgarra R, Del Sal G, Manfioletti G. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget, 2013;4:1293-1308.

49. Brun P, Giron MC, Qesari M, Porzionato A, Caputi V, Zoppellaro C, Banzato S, Grillo AR, Spagnol L, De Caro R, Pizzuti D, Barbieri V, **Rosato A**, Sturniolo GC, Martines D, Zaninotto G, Palù G, Castagliuolo I. Toll-like Receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology, 2013;145:1323-1333.

50. Melendez-Alafort L, Muzzio PC, **Rosato A**. Optical and multimodal peptide-based probes for In vivo molecular imaging. Anti-Cancer Agents Med Chem, 2012;12:476-499.

51. Martorelli D, Muraro E, Merlo A, Turrini R, Faè DA, **Rosato A**, Dolcetti R. Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-Virus-driven disorders. Clin Dev Immunol, 2012:931952.

52. Mariniello B, **Rosato A**, Zuccolotto G, Rubin B, Cicala MV, Finco I, M. Iacobone, Frigo AC, Fassina A, Pezzani R, Mantero F. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr-Relat Cancer, 2012;19:527-539.

53. Piccoli M, Franzin C, Bertin E, Urbani L, Blaauw B, Repele A, Taschin E, Cenedese A, Zanon GF, André-Schmutz I, **Rosato A**, Melki J, Cavazzana-Calvo M, Pozzobon M, De Coppi P. Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn(F7/F7) mouse model. Stem Cells, 2012;30:1675-1684.

54. Martorelli D, Guidoboni M, De Re V, Muraro E, Turrini R, Merlo A, Pasini E, Caggiari L, Romagnoli L, Spina M, Mortarini R, Gasparotto D, Mazzucato M, Carbone A, **Rosato A**, Anichini A, Dolcetti R. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B cell non-Hodgkin's lymphomas. Clin Cancer Res, 2012;18:4080-4091.

55. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, **Rosato A**, Bicciato S, Cordenonsi M, Piccolo S. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature, 2012;487:380-384.

56. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., **Rosato A.**, Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A., Daidone M.G., Dupont S., Basso G., Bicciato S., Piccolo S. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell, 2011;147:759-772.

57. Turrini R., Merlo A., Dolcetti R., Zanovello P., **Rosato A.** Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. Cancer Immunol Immunother, 2011;60:1639-1645.

58. Girardini J.E., Napoli M., Piazza S., Rustighi A., Marotta C., Radaelli E., Capaci V., Jordan L., Quinlan P., Thompson A., Mano M., **Rosato A.**, Crook T., Scanziani E., Means A.R., Lozano G., Schneider C., Del Sal G. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell, 2011;20:79-81.

59. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., **Rosato A.**, Francescato S., Basso G., Zanovello P., Onicescu G., Garrett-Mayer E., Montero A.J., Bronte V., Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011;118:2254-2265.

60. Merlo A., Turrini R., Dolcetti R., Zanovello P., **Rosato A.** Immunotherapy for EBV-associated malignancies. Int J Hematol, 2011;93:281-293.

61. Merlo A., Turrini, R., Bobisse S., Zamarchi R., Alaggio R., Dolcetti R., Mautner J., Zanovello P., Amadori A., **Rosato A.** Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol, 2010;184:5895-902.

62. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., **Rosato A.** The interplay between EBV and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematol-Hematol J, 2010;95:1769-77.

63. Martello G., **Rosato A.**, Ferrari F., Manfrin A., Cordenonsi M., Dupont S., Enzo E., Guzzardo V., Rondina M., Spruce T., Parenti A.R., Daidone M.G., Bicciato S., Piccolo S. A microRNA targeting Dicer for metastasis control. Cell, 2010;141:1195-207.

64. Martorelli D., Muraro E., Merlo A., Turrini R., **Rosato A.**, Dolcetti R. Role of CD4+ cytotoxic T lymphocytes in the control of infectious diseases and cancer. Int Rev Immunol, 2010;29:371-402.

65. Merlo A., Turrini R., Trento C., Zanovello P., Dolcetti R., **Rosato A**. 2010. Impact of γ-chain cytokines on EBV-specific T cell cultures. J Transl Med, 2010;8:121.

66. Bassi P.F., Volpe A., D'Agostino D., Palermo G., Renier D., Franchini S., **Rosato A.**, Racioppi M. 2010. Paclitaxel-Hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Guérin Refractory Carcinoma In Situ of the Bladder: Results of a Phase I Study. J Urol, 2010;185:445-449.

67. Rustighi A., Tiberi L., Soldano A., Napoli M., Nuciforo P., **Rosato A.**, Kaplan F., Capobianco A., Pece S., Di Fiore P.P., Del Sal G. The prolyl-isomerase Pin1 is a novel Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol, 2009;11:133-142.

68. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M., Guzzardo V., Parenti A.R., **Rosato A.**, Bicciato S., Balmain A., Piccolo S. A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell, 2009;137:87-98.

69. Montrone M., Martorelli D., **Rosato A.**, Dolcetti R. Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. Endocr. Metab. Immune Disord. Drug Targets, 2009;9:113-131.

70. Banzato A., Rondina M., Mélendez-Alafort L., Zangoni E., Nadali A., Renier D., Moschini G., Mazzi U., Zanovello P., **Rosato A.** Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nucl Med Biol, 2009;36:525-533.

71. Pasini E., Caggiari L., Dal Maso L., Martorelli D., Guidoboni M., Vaccher E., Barzan L., Franchin G., Gloghini A., De Re V., Sacchi N., Serraino D., Carbone A., **Rosato A.**, Dolcetti R. Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. Int J Cancer, 2009;125:1358-1364.

72. Ruzza P., **Rosato A.**, Rossi C.R., Floreani M., Quintieri L. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem, 2009;9:763-777.

73. Ruzza P., **Rosato A.**, Nassi A., Rondina M., Zorzin M., Rossi C.R., Floreani M., Quintieri L. Synthesis and preliminary in vitro biological evaluation of 4-[(4-hydroxyphenyl)sulfanyl]but-3-en-2-one, a 4-mercaptophenol derivative designed as a novel bifunctional antimelanoma agent. J Med Chem, 2009;52:4973-4976.

74. Meléndez-Alafort L., Nadali A., Zangoni E., Banzato A., Rondina M., **Rosato A.**, Mazzi U. Biokinetic and dosimetric studies of 188Re-Hyaluronic Acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. Nucl Med Biol, 2009;36:693-701.

75. Alaggio R., Bisogno G., **Rosato A.**, Ninfo V., Coffin C.M. Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. Hum Pathol, 2009;40:1600-1610.

76. Bobisse S., Rondina M., Merlo A., Tisato V., Mandruzzato S., Amendola M., Naldini L., Willemsen R.A., Debets R., Zanovello P., **Rosato A.** Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res, 2009;69:9385-9394.

77. Di Meo C., Panza L., Campo F., Capitani D., Mannina L., Banzato A., Rondina M., **Rosato A***, Crescenzi V. Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". Macromol Biosci, 2008;8:670-681. ***Corresponding author.**

78. Sebestyén Z., Schooten E., Sals T., Zaldivar I., San Josè E., Alarcón B., Bobisse S., **Rosato A.**, Szöllősi J., Gratama JW., Willemsen RA., Debets R. Human TCR

that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol, 2008;180:7736-7746.

79. Banzato A., Bobisse S., Renier D., Bettella F., Esposito G., Quintieri L., Mélendez-Alafort L., Mazzi U., Zanovello P., **Rosato A.** A paclitaxel-hyaluronic acid bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res, 2008;14:3598-3606.

80. Merlo A., Turrini R., Dolcetti R., Zanovello P. Amadori A., **Rosato A**. Adoptive cell therapy against EBV-related malignancies:a survey of clinical results. Expert Opin Biol Th, 2008;8:1265-1294.

81. Quintieri L., Fantin M., Palatini P., De Martin S., **Rosato A**., Caruso M., Geroni C., Floreani M. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes. Biochem Pharmacol, 2008;76:784-795.

82. Di Meo C., Panza L., Capitani D., Mannina L., Banzato A., Rondina M., Renier D., **Rosato A**., Crescenzi V. Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules, 2007;8:552-559.

83. Antoccia A., Banzato A., Bello M., Bollini D., de Notaristefani F., Giron C., Mazzi U., Menendez-Alafort L., Moschini G., Nadali A., Navarria F.L., Perrotta A., **Rosato A.**, Tanzarella C., Uzunov N. M. ^{188}Rhenium-induced cell death and apoptosis in a panel of tumor cell lines. Nucl Instrum Meth A, 2007;571:471-474.

84. Antoccia A., Baldazzi G., Banzato A., Bello M., Boccaccio P., Bollini D., de Notaristefani F., Mazzi U., Menendez-Alafort L., Moschini G., Navarria F.L., Pani R., Perrotta A., **Rosato A.**, Tanzarella C., Uzunov N. M. A YAP camera for the biodistribution of ^{188}Re conjugated with Hyaluronic-Acid in ‘‘in vivo’’ systems. Nucl Instrum Meth A, 2007;571:484-487.

85. Bobisse S., Zanovello P., **Rosato A.** T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. Expert Opin Biol Ther, 2007;7:1-14.

86. Parenti A., Leo G., Porzionato A., Zaninotto G., **Rosato A.**, Ninfo V. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. Hum Pathol, 2006;37:16-22.

87. **Rosato A.**, Zoso A., Dalla Santa S., Milan G., Del Bianco P., De Salvo GL., Zanovello P. 2006. Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative $CD8^+$ T cell parameters. J Immunol, 2006;176:1999-2006.

88. Casonato A., Pontara E., Sartorello F., Cattini M.G., Gallinaro L., Bertomoro A., **Rosato A.**, Padrini R., Pagnan A. Identifying type Vicenza von Willebrand disease. J Lab Clin Med, 2006;147:96-102.

89. **Rosato A.**, Banzato A., De Luca G., Renier D., Bettella F., Pagano C., Esposito G., Zanovello P., Bassi PF. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol, 2006;24:207-215.

90. **Rosato A.**, Pivetta M., Parenti A., Iaderosa G. A., Zoso A., Milan G., Mandruzzato S., Del Bianco P., Ruol A., Zaninotto G., Zanovello P. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer, 2006;119:1717-1722.

91. Coppola V., Barrick C.A., Bobisse S., Rodriguez-Galan M.C., Pivetta M., Reynolds D., Howard O.M., Palko M.E., Esteban P.F., Young H.A., **Rosato A.**, Tessarollo L. 2006. The scaffold protein cybr is required for cytokine-modulated trafficking of leukocytes in vivo. Mol Cell Biol, 2006;26:5249-5258.

92. Meléndez-Alafort L., Riondato M., Nadali A., Banzato A., Camporese D., Boccaccio P., Uzunov N., **Rosato A.**, Mazzi U. Bioavailability of ^{99m}Tc-HA-Paclitaxel complex [^{99m}Tc-ONCOFID-P] in mice using four different administration routes. J. Label. Compd. Radiopharm., 2006;49:939-950.

93. Antoccia A., Baldazzi G., Bello M., Bernardini D., Boccaccio P., Bollini D., de Notaristefani F., Garibaldi F., Hull G., Mazzi U., Moschini G., Muciaccio A., Navarria F.L., Cencelli VO., Pancaldi G., Pani R., Perrotta A., Riondato M., **Rosato A.**, Sgura A., Tanzarella C., Uzunov NM., Zuffa M. Preliminary study of metabolic radiotherapy with Re-188 via small animal imaging. Nucl Phys B-Proc Sup, 2006;150:411-416.

94. Teoli D. Parisi L., Realdon N., Guglielmi M., **Rosato A.**, Morpurgo M. Wet Sol-Gel derived silica for controlled release of proteins. J. Control. Release, 2006;116:295-303.

95. Quintieri L., Geroni C., Fantin M., Battaglia R., **Rosato A.**, Speed W., Zanovello P., Floreani M. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin. Cancer Res. 2005;11:1608-17.

96. Facchinetti A., Dalla Santa S., Mezzalira S., **Rosato A.**, Biasi G. A large number of T lymphocytes recognize Moloney-murine leukemia virus-induced antigens, but a few mediante long-lasting tumor immunosurveillance. J Immunol, 2005;174:5398-5406.

97. Pucciarelli S., Codello L., **Rosato A.**, Del Bianco P., Vecchiato G., Lise M. Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. Brit J Surg, 2003 ;90:66-71.

98. Dubey P., Su H., Adonai N., Du S., **Rosato A.**, Braun J., Gambhir SS., Witte ON. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc. Natl. Acad. Sci. U.S.A., 2003;100:1232-1237.

99. **Rosato A.**, Dalla Santa S., Zoso A., Giacomelli S., Milan G., Macino B., Tosello V., Della Bona P., Lollini P-L., De Giovanni C., Zanovello P. The cytotoxic T-lymphocyte response Against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 env product of an endogenous retrovirus. Cancer Res. 2003;63:2158-2163.

100. Macino B., Tosello V., Mandruzzato S., Bronte V., **Rosato A.**, Cingarlini S., Dalla Santa S., De Santo C., Marigo I., Rossi E., Zoso A., Gorza M., Zanovello P. Valutazione citometrica della risposta immunitaria mediata dai linfociti T

citotossici. Uso della tecnologia dei tetrameri. Quaderni di citometria pratica. A cura di G. Basso. Volume n° 2.

101. Cavallari I., D'Agostino D.M., Ferro T., **Rosato A.**, Barzon L., Pasquali C., Fogar P., Theodoropoulou M., Esposito G., Boscaro M., Pagotto U., Tebaldi E., Fallo F., Chieco-Bianchi L., Ciminale V. In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab, 2003;88:3893-3901.

102. Stievano L., Tosello V., Marcato N., **Rosato A.**, Sebelin A., Chieco-Bianchi L., Amadori A. CD8(+)alphabeta(+) T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol, 2003;171:4528-4538.

103. **Rosato A.**, Zoso A., Milan G., Macino B., Dalla Santa S., Tosello V., Di Carlo E., Musiani P., Whalen R.G., Zanovello P. 2003. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. J Immunol, 2003;171:5172-5179.

104. Silic-Benussi M., Cavallari I., Zorzan T., Rossi E., Hiraragi H., **Rosato A.**, Horie K., Saggioro D., Lairmore M.D., Willems L., Chieco-Bianchi L., D'Agostino D.M., Ciminale V. 2004. Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. Proc Natl Acad Sci USA, 2003;101:6629-6634.

105. Castiglioni P., Martin-Fontecha A., Milan G., Tomajer V., Magni F., Michaelsson J., Rugarli C., **Rosato A**., Bellone M. Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. Cancer Res, 2002;62:1116-22.

106. Indraccolo S., Gola E., **Rosato A.**, Minuzzo S., Habeler W., Tisato V., Roni V., Esposito G., Morini M., Albini A., Noonan D.M., Ferrantini M., Amadori A., Chieco-Bianchi L. Differential effects of angiostatin, endostatin and interferon-α_1 gene transfer on in vitro growth of human breast cancer cells. Gene Ther, 2002;9:867-78.

107. Quintieri L., **Rosato A.**, Napoli E., Sola F., Geroni C., Floreani M., Zanovello P. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubucin: role of cytochrome P450 3A. Cancer Res., 2000;60:3232-3238.

108. **Rosato A**., Milan G., Zambon A., Zanovello P., Collavo D. CTL analysis for tumor vaccines. 2000 In: DNA vaccines: Methods and Protocols. Humana Press, pp. 123-132.

109. **Rosato A**., Milan G., Cavinato M., Zoso A., Zanovello P. Optimization of a DNA vaccination protocol for CTL induction against tumors expressing the weakly immunogenic P1A antigen. In: Targeting of drugs – Strategies for gene constructs and delivery. IOS Press. NATO Science Series – Series A: Life Sciences, 2000;323:112-116.

110. Rampazzo P., Biasiolo A., Garin J., **Rosato A**., Betterle C., Ruffatti A., Pengo V. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost, 2001;85:57-62.

111. Quintieri L., **Rosato A.**, Amboldi N., Vizler C., Ballinari D., Zanovello P., Collavo D. Delivery of methoxymorpholinyl doxorubucin by IL-2-activated NK cells: effect in mice bearing hepatic metastases. Brit J Cancer, 1999;79:1067-1073.

112. Milan G., Zambon A., Cavinato M., Zanovello P., **Rosato A.**, Collavo D. Dissecting the immune response to Moloney-Murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach. J Virol, 1999;73:2280-2287.

113. Biasiolo A., Rampazzo P., Brocco T., Barbero F., **Rosato A**., Pengo V. [Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus, 1999;8:121-6.

114. **Rosato A.**, Milan G., Collavo D., Zanovello P. DNA-based vaccination against tumors expressing the P1A antigen. In: Methods. 1999;19:187-190.

115. Vizler C., **Rosato A.**, Calderazzo F., Quintieri L., Fruscella P., Wainstok de Calmanovici R., Mantovani A., Vecchi A., Zanovello P., Collavo D. Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity. Brit J Cancer, 1998;77:656-662.

116. Milan G., **Rosato A**., Zambon A., Zanovello P., Collavo D. DNA immunization in mice against virus-induced tumor antigens. Adv Exp Med Biol, 1998;451:311-314.

117. Indraccolo S., Feroli F., Minuzzo S., Mion M., **Rosato A.**, Zamarchi R., Titti F., Verani P., Amadori A., Chieco-Bianchi L. DNA immunization of mice against SIVmac239 gag and env using rev-independent expression plasmids. AIDS Res Hum Retrov, 1998;14:83-90.

118. Silvestri B., Calderazzo F., Coppola V., **Rosato A.**, Iacobelli S., Natoli C., Ullrich A., Sures I., Azam M., Brakebush C., Chieco-Bianchi L., Amadori A. Differential effect on TCR:CD3 stimulation of a 90 kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. Clin Exp Immunol, 1998;113:394-400.

119. Saggioro D., **Rosato A.**, Esposito G., Rosenberg M.P., Harrison J., Felber B.K., Pavlakis G.N., Chieco-Bianchi L. Inflammatory polyarthropathy and bone remodeling in HTLV-I Tax-transgenic mice. J Acq Immun Def Synd, 1997;14:272-280.

120. **Rosato A**., Zambon A., Milan G., Macino B., Quintieri L., Zanovello P., Collavo D. Cancer gene therapy by DNA immunization. Minerva Biotech., 1997;9:202-209.

121. D'Agostino D.M., Ciminale V., Zotti L., **Rosato A.**, Chieco-Bianchi L. The human T-cell lymphotropic virus type I Tof protein contains a bipartite nuclear localization signal that is able to functionally replace the amino-terminal domain of Rex. J Virol, 1997;71:75-83.

122. **Rosato A.**, Zambon A., Milan G., Ciminale V., D'Agostino D.M., Macino B., Zanovello P., Collavo D. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen

P815A. Hum Gene Ther, 1997;8:1451-1458.

123. Iezzi G., Rivolta L., Ronchetti A., Martin-Fontecha A., **Rosato A.**, Protti M.P., Sabbadini M.G., Bellone M. The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes. Cancer Res, 1997;57:2564-2568.

124. **Rosato A.**, Zambon A., Macino B., Mandruzzato S., Bronte V., Milan G., Zanovello P., Collavo D. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. Int J Cancer, 1996;65:847-851.

125. Bronte V., Macino B., Zambon A., **Rosato A.**, Mandruzzato S., Zanovello P., Collavo D. Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. Biochem Bioph Res Co, 1996;218:344-351.

126. Monastra G., Cabrelle A., Zambon A., **Rosato A.**, Macino B., Collavo D., Zanovello P. Membrane form of TNFa induces both cell lysis and apoptosis in susceptible target cells. Cell Immunol, 1996;171:102-110.

127. Macino B., Zambon A., Milan G., Cabrelle A., Ruzzene M., **Rosato A.**, Mandruzzato S., Quintieri L., Zanovello P., Collavo D. CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. Biochem Bioph Res Co, 1996;226:769-776.

128. **Rosato A.**, Mandruzzato S., Bronte V., Zambon A., Macino B., Calderazzo F., Zanovello P., Collavo D. Role of anti-LFA-1 and anti-ICAM-1 combined mAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV). Int J Cancer, 1995;61:355-362.

129. Mandruzzato S., **Rosato A.**, Bronte V., Zanovello P., Amboldi N., Ballinari D., Collavo D. Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutical effect in mice bearing lung metastases. Cancer Res, 1994;54:1016-1020.

130. Macino B., Zambon A., Bronte V., **Rosato, A.**, Mandruzzato S., Calderazzo F., Mezzalira S., Zanovello P., Collavo D. Studio dei segnali intracellulari coinvolti nell'induzione della morte cellulare programmata. In: Immunologia 1994. Monduzzi Ed. pp. 647-650.

131. **Rosato A.**, Zambon A., Mandruzzato S., Bronte V., Macino B., Calderazzo F., Collavo D., Zanovello P. Inhibition of protein tyrosine phosphorylation prevents T-cell-mediated cytotoxicity. Cell Immunol, 1994;159:294-305.

132. Bronte V., Zanovello P., **Rosato A.**, Zambon A., Mandruzzato S., Pizzo P., Di Virgilio F., Collavo D. Synergistic effect of extracellular Adenosine 5'-Triphosphate and Tumor Necrosis Factor on DNA degradation. Cell Immunol, 1993;152:110-119.

133. **Rosato A.**, Bronte V., Pollis F., Mandruzzato S., Zambon A., Zanovello P., Collavo D. The in vivo role of Leukocyte Function-Associated Antigen-1 in cytotoxic cell activity against tumors induced by Moloney-murine sarcoma/leukemia retroviral complex. Leukemia, 1992;6:166-167.

134. Pollis F., **Rosato A.**, Bronte V., Mandruzzato S., Zambon A., Zambello R., Pizzo P., Zanovello P. Interaction of Large Granular Lymphocytes with susceptible target does not induce second messenger and cytolytic granule exocytosis. Leukemia, 1992;6:92-93.

135. Zanovello P., **Rosato A.**, Bronte V., Mandruzzato S., Cerundolo V., Collavo D. Anti tumor efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. Cancer Immunol Immunother, 1992;35:27-32.

136. Mandruzzato S., **Rosato A.**, Bronte V., Pollis F., Zambon A., Zanovello P., Collavo D. Therapeutical effect of 4'-Deoxy-4'-Iododoxorubicin-loaded LAK cells in mice bearing lung metastases. Pharmacol Res, 1992;26:124-125.

137. Pollis F., Bronte V., Mandruzzato S., **Rosato A.**, Zambon A., Zanovello P., Zambello R., Callegaro L., Collavo D. Inhibition of CTL-line lysis after gangliosides treatment. Pharmacol Res, 1992;26:190-191.

138. **Rosato A.**, Bronte V., Mandruzzato S., Zambon A., Calderazzo F., Biasi G., Zanovello P., Collavo D. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. Int J Cancer, 1992;supplement 7:24-27.

139. Zanovello P., **Rosato A.**, Bronte V., Cerundolo V., Collavo D. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins. Ann Ist Super Sanita, 1991;27:91-95.

140. Collavo D., Zanovello P., **Rosato A.**, Bronte V., Facchinetti A., Biasi G. 1991. La risposta immunologica verso antigeni tumorali specifici. In: I modificatori della risposta biologica. pp. 15-20.

141. Zanovello P., Vallerani E., Bronte V., **Rosato A.**, Chieco-Bianchi L., Collavo D. Tolerance induction in adult mice intrathymically injected with Moloney murine leukemia virus and treated with cyclophosphamide. J Immunol Res, 1990;2:151-156.

142. Zanovello P., Vallerani E., Bronte V., **Rosato A.**, Collavo D., Chieco-Bianchi L. Tolerance induction and leukemia development in M-MuLV intrathymically injected adult mice treated with cyclophosphamide. Arch Geschwulstforsch 1990;60:423-428.

143. Zanovello P., Bronte V., **Rosato A.**, Pizzo P., Di Virgilio F. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol, 1990;145:1545-1550.

144. Collavo D., Zanovello P., Bronte V., **Rosato A.**, Biasi G. 1990. Meccanismi molecolari della lisi mediata dai linfociti citotossici. Aggiornamento del medico. 14:720-726.

145. Zanovello P., **Rosato A.**, Bronte V., Cerundolo V., Treves S., Di Virgilio F., Pozzan T., Biasi G., Collavo D. Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. J Exp Med, 1989;170:665-677.